Subtypes and Prognostic Factors in Erdheim-Chester Disease

Erdheim-Chester Disease Clinical Trial

Official title:

Subtypes and Prognostic Factors in Erdheim-Chester Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06317246
• Other study ID #: ECDSUB
• Status: Recruiting
• Phase: N/A
• Start date: September 15, 2020
• Est. completion date: December 15, 2024

Study information

• Verified date: March 2024
• Source: Meyer Children's Hospital IRCCS
• Contact: Augusto Vaglio
• Phone: 3200026532
• Email: augusto.vaglio[@]meyer.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Erdheim-Chester Disease (ECD) is a rare form of histiocytosis characterized by the proliferation of blood cells, known as histiocytes, which infiltrate various organs and tissues, often causing irreversible damage. The causes of the pathology are still unknown. Although the disease typically affects adult individuals, cases of pediatric-onset ECD have been described. However, there is a lack of detailed information on the phenotypic characteristics of these patients, and reliable data on response to specific therapies and long-term outcomes are missing. Three patients referred to our reference center for Histiocytosis present a concomitant BRAF-mutated neoplasm. Such an association could be due to the presence of mosaicisms for the BRAF V600E mutation. Mosaicism is a biological event defined as the presence of more than one genetically dissimilar cell population in the same organism and is an increasingly studied field, both in normal and pathological conditions. If proven in ECD as well, this mechanism could contribute to providing answers to the still open questions regarding the development of this disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 70
• Est. completion date: December 15, 2024
• Est. primary completion date: September 15, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Year to 65 Years

Eligibility

Inclusion Criteria:

• Prevalent and incident patients (adults and pediatric), with histologically confirmed diagnosis of Erdheim-Chester Disease according to the latest diagnostic recommendations;

• Signing of informed consent for study participation.

Exclusion Criteria:

• Patients for whom clinical and imaging data are not available and for whom it is not possible to retrieve histological samples."

Related Conditions & MeSH terms

• Erdheim-Chester Disease

Intervention

Genetic:
• Investigation of BRAF mosaicism
The study of BRAF mosaicism will be conducted on biopsy samples from patients with ECD and other neoplasms co-occurring with the BRAFV600E mutation. The samples will be labeled with anti-Pu.1-Alexa Fluor 647 antibody (which binds to macrophages), then DNA will be extracted using FACS method and amplified using MDA (Qiagen Repli-G Single-Cell kit). Quality control will be performed using Quant-it (ThermoScientific) and Agilent 4200 TapeStation. Eligible samples will undergo digital droplet PCR (ddPCR) and sequencing. ddPCR probes for wild-type and mutant alleles will be used. Sequencing will be performed using Illumina HiSeq 2500 system

Locations

Country	Name	City	State
Italy	Meyer Children's Hospital IRCCS	Florence	Firenze
Italy	AOU Parma	Parma

Sponsors (1)

Lead Sponsor	Collaborator
Meyer Children's Hospital IRCCS

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Clinical characteristics of patients with Erdheim-Chester Disease	Evaluation of clinical characteristics in extreme subtypes of Erdheim-Chester Disease	4 years
Primary	Prognostic factors of patients with Erdheim-Chester Disease	Evaluation of prognostic factors in extreme subtypes of Erdheim-Chester Disease	4 years